Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2019

View Archived Issues

Integrated stress response backfires in Down syndrome

Researchers create new rat and pig models of cystic fibrosis

Novel potent OXE receptor antagonists with prolonged plasma lifetime for eosinophilic diseases

Positive data presented for WP-1220 in patients with CTCL

Novel prostate cancer bone metastasis model in humanized mice

Seviprotimut-L demonstrates safety and efficacy in part B1 of MAVIS phase III study

RQ-00490721 prevents cardiac dysfunction in mouse model of heart failure

Haplodeficiency disrupts microglial responses in AD models

Celldex begins phase Ia study with KIT inhibitor CDX-0159

DWP-212525, a next-generation therapeutic for autoimmune diseases

COR-001 suppresses hsCRP in patients with chronic kidney disease

Phase III study of vericiguat in worsening chronic heart failure meets primary endpoint

Phase III dosing defined for lixivaptan in autosomal dominant polycystic kidney disease

Scholar Rock reports preliminary PK and PD data from phase II study of SRK-015 in SMA

New ASK1/TAK1 dual kinase inhibitor for treating NASH presented

Shanghai Longwood Biopharmaceuticals divulges compounds for HBV

Preliminary clinical data on CRISPR/Cas9 gene-editing therapy CTX-001 in severe hemoglobinopathies

Enanta Pharmaceuticals patents MAP3K5 inhibitors

Adenosine A2A receptor antagonist DZD-2269 overcomes adenosine-induced immunosuppression

ORIC Pharmaceuticals presents CD73 inhibitors

Amgen identifies novel apelin receptor agonists

REVOLUTION Medicines patents mTOR inhibitors

New phase III trial in Japan studies KW-3357 to treat early-onset pre-eclampsia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...